Mechanistic target of rapamycin complex 1 (mTORC1) via FKBP12–mTOR FRB complex (mTORC1 (FKBP12-FRB))

The mechanistic target of rapamycin complex 1 (mTORC1) is a master regulator of cellular metabolism, growth, and survival that integrates signals from nutrients, energy levels, and growth factors (UniProt P42345). This specific target refers to the inhibition of mTORC1 through the formation of a ternary complex involving the immunophilin FKBP12 and the FRB (FKBP12-rapamycin binding) domain of the mTOR protein. Drugs like rapamycin (sirolimus) and its analogs (rapalogs) act as molecular glues, binding first to FKBP12 and then to the FRB domain, which allosterically inhibits the kinase activity of the complex (PubMed: 25274303). Dysregulation of the mTORC1 pathway is a hallmark of various pathologies, including many types of cancer, where it promotes uncontrolled cell proliferation and protein synthesis (PubMed: 31036703). It also plays a critical role in genetic disorders like tuberous sclerosis complex (TSC) and is a key target for immunosuppression in organ transplantation (StatPearls: Sirolimus). Clinically, targeting the FKBP12-mTOR FRB interface allows for selective inhibition of mTORC1 over mTORC2, although chronic treatment can eventually affect both complexes (PubMed: 15268862). Monitoring biomarkers such as the phosphorylation of downstream targets like S6K1 and 4E-BP1 is essential for assessing therapeutic efficacy and patient response (PubMed: 21849461).

Other names

mTORC1Mammalian target of rapamycin complex 1FKBP12-rapamycin-mTOR complexFRB domain of mTORmTOR-Raptor complexFKBP12-rapamycin-binding domain of mTOR

Rapalogs (e.g., sirolimus) act as allosteric inhibitors by forming a gain-of-function complex with the immunophilin FKBP12. This drug-FKBP12 complex binds specifically to the FRB domain of mTOR, which sterically blocks the recruitment of substrates and inhibits the phosphorylation of downstream targets like S6K1 and 4E-BP1 (PubMed: 25274303, 15268862).